OMERS ADMINISTRATION Corp Purchases Shares of 7,665 United Therapeutics Corporation $UTHR

OMERS ADMINISTRATION Corp purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, Holdings Channel reports. The fund purchased 7,665 shares of the biotechnology company’s stock, valued at approximately $4,153,000.

A number of other large investors also recently modified their holdings of UTHR. BlackRock Inc. acquired a new stake in shares of United Therapeutics in the second quarter valued at about $2,868,735,000. Avoro Capital Advisors LLC boosted its position in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. Wellington Management Group LLP boosted its position in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC boosted its position in United Therapeutics by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after purchasing an additional 295,221 shares during the last quarter. Finally, Janus Henderson Group PLC grew its stake in United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after purchasing an additional 70,829 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $545.83, for a total value of $5,185,385.00. Following the sale, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,113,210.79. This represents a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $10,311,581.28. The trade was a 34.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 434,075 shares of company stock worth $233,340,010 over the last three months. 8.60% of the stock is owned by insiders.

Analysts Set New Price Targets

UTHR has been the topic of several recent analyst reports. Bank of America lowered their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Morgan Stanley set a $515.00 price objective on United Therapeutics in a report on Thursday, August 6th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $646.00.

United Therapeutics Stock Up 1.1%

Shares of NASDAQ UTHR opened at $518.53 on Wednesday. The business’s 50 day moving average price is $531.75 and its two-hundred day moving average price is $538.30. The company has a market cap of $22.24 billion, a PE ratio of 18.55, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59. United Therapeutics Corporation has a twelve month low of $302.19 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same period last year, the firm posted $6.41 earnings per share. The business’s revenue was down 1.9% on a year-over-year basis. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.